Aptevo Therapeutics Inc (APVO)
0.5094
-0.03
(-5.32%)
USD |
NASDAQ |
Jun 25, 16:00
0.5094
0.00 (0.00%)
After-Hours: 20:00
Aptevo Therapeutics Cash from Financing (Quarterly): -0.003M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.003M |
| December 31, 2023 | 3.046M |
| September 30, 2023 | 4.344M |
| June 30, 2023 | 0.481M |
| March 31, 2023 | -1.873M |
| December 31, 2022 | 5.998M |
| September 30, 2022 | -0.50M |
| June 30, 2022 | -3.178M |
| March 31, 2022 | -4.936M |
| December 31, 2021 | -3.076M |
| September 30, 2021 | -3.021M |
| June 30, 2021 | 8.316M |
| March 31, 2021 | 23.94M |
| December 31, 2020 | 21.25M |
| September 30, 2020 | 24.73M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | -22.10M |
| December 31, 2019 | -0.135M |
| September 30, 2019 | 0.024M |
| Date | Value |
|---|---|
| June 30, 2019 | -0.113M |
| March 31, 2019 | 20.37M |
| December 31, 2018 | 0.039M |
| September 30, 2018 | -0.583M |
| June 30, 2018 | 0.313M |
| March 31, 2018 | -0.556M |
| December 31, 2017 | 0.527M |
| September 30, 2017 | -0.182M |
| June 30, 2017 | -0.006M |
| March 31, 2017 | 19.20M |
| December 31, 2016 | 1.106M |
| September 30, 2016 | 55.29M |
| June 30, 2016 | 19.28M |
| March 31, 2016 | 13.62M |
| December 31, 2015 | 9.359M |
| September 30, 2015 | 9.219M |
| June 30, 2015 | 18.37M |
| March 31, 2015 | 14.38M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-22.10M
Minimum
Mar 2020
24.73M
Maximum
Sep 2020
2.660M
Average
-0.0015M
Median
Cash from Financing (Quarterly) Benchmarks
| Johnson & Johnson | 546.00M |
| BioSig Technologies Inc | 1.54M |
| Adial Pharmaceuticals Inc | 3.824M |
| IN8bio Inc | -0.277M |
| NovaBay Pharmaceuticals Inc | -0.597M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.651M |
| Free Cash Flow | -22.95M |
| Free Cash Flow Per Share (Quarterly) | -9.685 |
| Free Cash Flow Yield | -11.63K% |